Inclusive
7078
Renascience
4889
Chordia Therapeutics
190A
Kufu Company Holdings
4376
Cube
7112
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 7.59%7.79B | 4.60%1.98B | 5.79%1.94B | 12.52%2B | 7.71%1.87B | 11.48%7.24B | 16.28%1.89B | 3.70%1.83B | 16.28%1.78B | 10.59%1.74B |
Cost of revenue | 12.87%2.39B | 7.43%613.5M | 9.03%601.65M | 19.21%613.14M | 16.94%565.92M | 15.32%2.12B | 24.87%571.09M | 11.39%551.8M | 16.94%514.35M | 8.30%483.95M |
Gross profit | 5.40%5.39B | 3.37%1.36B | 4.39%1.34B | 9.79%1.39B | 4.14%1.3B | 9.96%5.11B | 12.92%1.32B | 0.71%1.28B | 16.02%1.26B | 11.51%1.25B |
Operating expense | 3.74%4.84B | 4.82%1.29B | 5.74%1.22B | 1.48%1.19B | 2.86%1.14B | 5.52%4.67B | 4.84%1.23B | 4.49%1.16B | 9.72%1.18B | 3.14%1.1B |
Staff costs | 7.36%2.87B | ---- | ---- | ---- | ---- | 3.80%2.67B | ---- | ---- | ---- | ---- |
Selling and administrative expenses | 0.01%912.38M | ---- | ---- | ---- | ---- | 17.21%912.27M | ---- | ---- | ---- | ---- |
-Selling and marketing expense | 19.49%43.41M | ---- | ---- | ---- | ---- | -9.60%36.33M | ---- | ---- | ---- | ---- |
-General and administrative expense | -0.80%868.97M | ---- | ---- | ---- | ---- | 18.67%875.94M | ---- | ---- | ---- | ---- |
Depreciation and amortization | 9.32%175.91M | ---- | ---- | ---- | ---- | 17.30%160.91M | ---- | ---- | ---- | ---- |
-Depreciation | 9.32%175.91M | ---- | ---- | ---- | ---- | 17.30%160.91M | ---- | ---- | ---- | ---- |
Rent and land expenses | -2.97%443.85M | ---- | ---- | ---- | ---- | -0.54%457.45M | ---- | ---- | ---- | ---- |
Other operating expenses | -5.09%439.5M | ---- | ---- | ---- | ---- | -1.88%463.1M | ---- | ---- | ---- | ---- |
Operating profit | 22.61%550.54M | -16.20%76.2M | -8.09%114.68M | 122.54%192.7M | 13.78%166.97M | 95.41%449.03M | 2,776.04%90.93M | -24.59%124.77M | 425.52%86.59M | 186.23%146.75M |
Net non-operating interest income (expenses) | -28.60%337K | -27.35%85K | -29.17%85K | -28.81%84K | -29.06%83K | -21.07%472K | -21.48%117K | -21.57%120K | -21.85%118K | -19.31%117K |
Non-operating interest income | -29.17%340K | -28.57%85K | -29.51%86K | -29.17%85K | -29.41%84K | -22.08%480K | -22.22%119K | -21.79%122K | -22.08%120K | -22.22%119K |
Non-operating interest expense | -62.50%3K | --0 | -50.00%1K | -50.00%1K | -50.00%1K | -55.56%8K | -50.00%2K | -33.33%2K | -33.33%2K | -75.00%2K |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | 78.18%-23.33M | 77.77%-23.33M | -22.08%-106.94M | -19.84%-104.97M | ||||||
Less:Other special charges | -86.56%264K | ---- | ---- | ---- | ---- | -87.42%1.97M | --0 | ---- | ---- | ---- |
Less:Write off | -78.02%23.07M | ---- | ---- | ---- | ---- | 45.84%104.97M | ---- | ---- | ---- | ---- |
Other non-operating income (expenses) | -78.61%26.13M | 12.71%9.35M | -2.37%7.58M | -71.75%5.09M | -95.32%4.13M | -69.65%122.19M | -77.09%8.29M | -95.74%7.76M | -71.68%18M | -27.04%88.13M |
Income before tax | 19.13%553.67M | 1,204.52%62.28M | -6.38%122.34M | 88.96%197.87M | -27.16%171.18M | -14.78%464.75M | 89.69%-5.64M | -62.41%130.68M | 30.55%104.71M | 36.46%234.99M |
Income tax | -9.14%157.21M | 172.03%16.56M | -20.29%38.12M | 86.66%74.46M | -64.57%28.07M | -13.64%173.02M | 145.60%6.09M | -59.37%47.82M | 17.60%39.89M | 27.64%79.23M |
Net income | 35.90%396.46M | 489.83%45.72M | 1.65%84.23M | 90.38%123.41M | -8.13%143.11M | -15.45%291.72M | 71.61%-11.73M | -63.96%82.86M | 40.05%64.82M | 41.42%155.77M |
Net income continuous operations | 35.90%396.46M | 489.84%45.72M | 1.64%84.23M | 90.38%123.41M | -8.13%143.11M | -15.45%291.72M | 71.61%-11.73M | -63.96%82.86M | 40.04%64.82M | 41.43%155.77M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 35.90%396.46M | 489.83%45.72M | 1.65%84.23M | 90.38%123.41M | -8.13%143.11M | -15.45%291.72M | 71.61%-11.73M | -63.96%82.86M | 40.05%64.82M | 41.42%155.77M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 35.90%396.46M | 489.83%45.72M | 1.65%84.23M | 90.38%123.41M | -8.13%143.11M | -15.45%291.72M | 71.61%-11.73M | -63.96%82.86M | 40.05%64.82M | 41.42%155.77M |
Gross dividend payment | ||||||||||
Basic earnings per share | 35.91%274.33 | 490.14%31.64 | 1.66%58.28 | 90.39%85.39 | -8.13%99.02 | -15.45%201.85 | 71.63%-8.11 | -63.96%57.33 | 40.07%44.85 | 41.43%107.78 |
Diluted earnings per share | 35.91%274.33 | 489.85%31.6356 | 1.65%58.2778 | 90.38%85.3874 | -8.13%99.02 | -15.45%201.85 | 71.62%-8.1149 | -63.96%57.33 | 40.07%44.85 | 41.43%107.78 |
Dividend per share | 20.00%30 | 20.00%30 | 0 | 0 | 0 | 25.00%25 | 25.00%25 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |